The Global Pharmacogenomics Market was valued at US$ 5.58 Billion in 2024 and is expected to grow at a CAGR of 10.6% from 2024 to 2034. In 2024, North America led the market, achieving over 48.5% share with a revenue of US$ 2.7 Billion.

In 2025, the Pharmacogenomics Market is gaining momentum with precision tailoring of psychiatric and pain medications. Pharmacogenomic-guided tools are being used to inform antidepressant selection, reducing the typical trial-and-error period from weeks to days. Pain management clinics are applying CYP2D6 and OPRM1 genotyping to guide opioid prescribing—minimizing risk of under- or overdosing. Software platforms interpret test results and provide clinician prompts formatted in clear dosing recommendations. Since implementation, practices have seen a 25% increase in medication response rates and significantly lower incidence of adverse psychoactive effects.

Medical groups are integrating genetic counselors into care teams to discuss results with patients. The growing use of pharmacogenomics in mental health and pain care reflects a shift toward safer, faster, and more empathetic prescribing—elevating effectiveness and patient trust in treatment.

Click here for more information: https://market.us/report/pharmacogenomics-market/

Key Takeaways

• The Pharmacogenomics market generated a revenue of US$ 5.6 Billion and is predicted to reach US$ 15.3 Billion, with a CAGR of 10.6%.
• Based on the Technology, the Polymerase Chain Reaction segment generated the most revenue for the market with a market share of 45.9%.
• Based on the application, the Oncology segment generated the most revenue for the market with a market share of 35.2%.
• Based on the End-User, the Hospital & Clinics segment generated the most revenue for the market with a market share of 48.7%.
• Region-wise, North America remained the lead contributor to the market, by claiming the highest market share, amounting to 48.5%.

Key Market Segments

By Technology

• Sequencing
• Microarray
• Polymerase Chain Reaction
• Others

By Application

• Drug Discovery
• Infectious Diseases
• Oncology
• Cardiovascular Diseases
• Other Applications

By End-User

• Hospital & Clinics
• Research Organizations
• Others

Emerging Trends

1. Antidepressant pharmacogenomic panels shortening treatment timelines.
2. Genotyping for opioid metabolizer status reducing pain management risks.
3. Clinical-genomic dashboards offering dosing recommendations.
4. Genetic counselor integration into mental health workflows.

Use Cases

1. A psychiatrist orders PGx testing to predict SSRI response for a new patient.
2. Pain clinic genotypes CYP2D6 to adjust codeine dosage safely.
3. Platform alert suggests nortriptyline over amitriptyline based on genotype.
4. Counselors explain PGx results and dosing implications in follow-up appointments.